These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 10612015)

  • 1. Cost-effectiveness of faecal occult blood screening for colorectal cancer: results of the Nottingham trial.
    Whynes DK
    Crit Rev Oncol Hematol; 1999 Nov; 32(2):155-65. PubMed ID: 10612015
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial.
    Whynes DK;
    J Med Screen; 2004; 11(1):11-5. PubMed ID: 15006108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for colorectal cancer: what are the costs?
    Weller D; Moss J; Hiller J; Thomas D; Edwards J
    Int J Technol Assess Health Care; 1995; 11(1):26-39. PubMed ID: 7706012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of colorectal cancer screening with computed tomography colonography or fecal blood tests.
    Heresbach D; Chauvin P; Grolier J; Josselin JM
    Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1372-9. PubMed ID: 20802341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness studies fan colonoscopy debate.
    Newman L
    J Natl Cancer Inst; 2000 Nov; 92(22):1796-8. PubMed ID: 11078753
    [No Abstract]   [Full Text] [Related]  

  • 6. Faecal occult blood screening for colorectal cancer: is it cost-effective?
    Whynes DK; Neilson AR; Walker AR; Hardcastle JD
    Health Econ; 1998 Feb; 7(1):21-9. PubMed ID: 9541081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effective screening strategies for colorectal cancer.
    Whynes DK; Walker AR; Hardcastle JD
    J Public Health Med; 1992 Mar; 14(1):43-9. PubMed ID: 1599742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Divergent understanding of health professionals regarding correct subsequent management of an asymptomatic patient with a positive faecal occult blood test and negative colonoscopy with resultant cost implications.
    Beswick L; Ting A; Macrae F; Dowling D; Hair C
    Intern Med J; 2014 Dec; 44(12a):1264-5. PubMed ID: 25442767
    [No Abstract]   [Full Text] [Related]  

  • 9. Mathematical models and cost-effective screening strategies for colorectal cancer.
    Smith RA
    CMAJ; 2010 Sep; 182(12):1283-4. PubMed ID: 20713572
    [No Abstract]   [Full Text] [Related]  

  • 10. The relative economics of screening for colorectal cancer, breast cancer and cervical cancer.
    Gyrd-Hansen D
    Crit Rev Oncol Hematol; 1999 Nov; 32(2):133-44. PubMed ID: 10612013
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
    Sonnenberg A; Delcò F; Inadomi JM
    Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal cancer screening in Italy: feasibility and cost-effectiveness in a model area.
    Sorrentino D; Paduano R; Bernardis V; Piccolo A; Bartoli E
    Eur J Gastroenterol Hepatol; 1999 Jun; 11(6):655-60. PubMed ID: 10418938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of screening by faecal occult blood testing for colorectal cancer in Australia.
    Salkeld G; Young G; Irwig L; Haas M; Glasziou P
    Aust N Z J Public Health; 1996 Apr; 20(2):138-43. PubMed ID: 8799087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation.
    Daniels K; McKee M
    J R Army Med Corps; 1995 Oct; 141(3):142-50. PubMed ID: 8568748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Colorectal cancer screening is profitable].
    Pikkarainen P
    Duodecim; 1999; 115(17):1813-4. PubMed ID: 11941648
    [No Abstract]   [Full Text] [Related]  

  • 16. The impact of CT colonography for colorectal cancer screening on the UK NHS: costs, healthcare resources and health outcomes.
    Sweet A; Lee D; Gairy K; Phiri D; Reason T; Lock K
    Appl Health Econ Health Policy; 2011; 9(1):51-64. PubMed ID: 21174482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faecal occult blood test screening for colorectal cancer--what are we waiting for?
    Stanley AJ; St John DJ
    Aust N Z J Med; 1999 Aug; 29(4):545-51. PubMed ID: 10868533
    [No Abstract]   [Full Text] [Related]  

  • 18. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for colon cancer: economics and related considerations.
    Gelfand DW
    Semin Roentgenol; 1996 Apr; 31(2):170-6. PubMed ID: 8848734
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.